Latest
Boston Scientific Taxus Stent
& Related Newswire
6/27/2006 2:25:00 PM | Medtronic drug-eluting stent advancing 
=(0) Medtronic reports on the status of several studies on its coronary stent: Patient enrollment is complete in the fourth phase of a study, which compares the Medtronic Endeavor stent to the Boston Scientific Taxus Stent. Both are stents that release medication into the patient's bloodstream. A study is also under way to compare the Endeavor to Johnso...
Read More
6/22/2006 1:45:00 PM | Angiotech shares drop on report of lower stent use =(0) Contrary to a report in the Wall Street Journal, officials at Angiotech, a company that makes drug preparations for stents, say that the use of drug-coated stents is not declining and that they remain more effective than bare metal stents. The Journal report had stated that hospitals were concerned about the formation of blood clots so had beg...
Read More
6/16/2006 7:02:00 AM | Johnson & Johnson to appeal stent ruling =(0) Boston Scientific has scored a point in their patent war against Johnson & Johnson. The companies are claiming each infringed the patents of the other with regard to various models of stents, wire mesh devices that are placed inside arteries. The latest ruling upholds a previous decision that Johnson & Johnson's Cypher stent infringed Bos...
Read More
6/12/2006 12:59:00 PM | Boston Scientific Says Data Reinforces Benefits Of TAXUS Stents In ... =(0) Boston Scientific Corp. states that statistics from the multi-center STENT registry show that patients with its TAXUS Express2 paclitaxel-eluting stent system have better outcomes than patients with Johnson & Johnson's Cypher sirolimus-eluting stent system. The study was comprised of over 5000 patients who received one of the two stents at eig...
Read More
5/16/2006 4:01:00 PM | Boston Scientific stent gets added EU OK =(0) Boston Scientific's Taxus Liberte stent has received approval in Europe for the treatment of additional conditions. Originally, approval was granted for coronary artery disease; now the drug-coated stent may be used to treat in-stent restinosis (tissue overgrowth of a stent) and total arterial occlusion (total blockage). This new stent i...
Read More
4/18/2006 2:17:00 PM | Boston Scientific net down as heart device sales slow =(0) Boston Scientific reported slower sales of its drug-coated stent this past quarter, due to decreased demand and competition from the other maker of this type of device, Johnson & Johnson. The FDA has communicated some quality concerns to the company, but they say they are on track for the release of a new version of the Taxus Stent later this ...
Read More